Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0IGJOE
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
CN110072556B 1x-9574
|
|||||
| Synonyms |
1x-9574
Click to Show/Hide
|
|||||
| Organization |
BAYER PHARMA AKTIENGESELLSCHAFT
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
4.12
|
|||||
| Structure |
|
|||||
| Antibody Name |
TPP-9574
|
Antibody Info | ||||
| Antigen Name |
C-X-C chemokine receptor type 5 (CXCR5)
|
Antigen Info | ||||
| Payload Name |
KSP Inhbitor
|
Payload Info | ||||
| Therapeutic Target |
Kinesin spindle protein (KSP)
|
Target Info | ||||
| Linker Name |
CN110072556B+Conjugate1+Linker
|
Linker Info | ||||
| Conjugate Type |
Random conjugation through reduced inter-chain cysteines.
|
|||||
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 0.0294 nM | Positive CXCR5 expression (CXCR5+++/++) | ||
| Method Description |
Cell line Rec-1 were plated at set initial densities in 96-well culture plate with white bottom in the appropriate growth media. 48hours later, the medium was replaced. The ADCs in 10 ul of culture medium inconcentrations from 10-5M to 10-13M were then pipetted to the cells. After 6 hours of incubation at 37°C and 5%carbon dioxide, the medium was changed and the antibody-drug conjugates or metabolites were added by pipette in 10 ul of culture medium in concentrations of 10-5M to 10-13M to the cells (triplicates) in 90 ul. After 96 h, the cell proliferation was detected using the MTT assay (ATCC, Manassas, Virginia, USA, catalogue No. 30-1010K). To this end, the MTT reagent was incubated with the cells for 4 h, followed by lysis of the cells overnight byaddition of the detergent. The dye formed was detected at 570 nm (Infinite M1000 proTecan). The measured data were used to calculate the ICso of the growth inhibition usingthe DRC (dose response curve). The proliferation of cells which were not treated with testsubstance but were otherwise identically treated was defined as the 100% figure.
Click to Show/Hide
|
||||
| In Vitro Model | Mantle cell lymphoma | REC-1 cells | CVCL_1884 | ||
